Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). ET-900 expands Eton’s pipeline into infantile and refractory epileptic spasms using mecasermin injection.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ET-900 expands Eton’s pipeline into infantile and refractory epileptic spasms using mecasermin injection
- Baylor College of Medicine license secures patent rights for IGF-1 use in spasms
- FDA research IND submitted for investigator-sponsored Phase 2 study in children with refractory epileptic spasms
- Initial enrollment and dosing targeted for Q1 2027, creating a near-term clinical development milestone
Item EX-99.1 · Exhibit EX-99.1
- ET-900 expands INCRELEX’s potential indications into infantile and epileptic spasms through licensed Baylor College of Medicine patent rights
- FDA IND submitted for investigator-sponsored Phase 2 study, with first dosing targeted for Q1 2027
- Trial expected to enroll up to 20 children ages 2–18 across three sites with refractory spasms
- Preclinical IGF-1 treatment reduced daily spasms approximately 50% and eliminated spasms in 20% of treated animals
- Eton retains commercial rights, supporting planned entry into pediatric neurology while adding clinical development risk beyond INCRELEX’s approved use
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.